FDA’s own report shows no child deaths definitively caused by COVID vaccination

FDA Report Finds No Definitive Child Deaths from COVID Vaccines

The FDA's long-awaited analysis of adverse events related to COVID-19 vaccines in children found no definitive link between the vaccines and pediatric deaths. The report, dated December 5, flagged 96 "unique" pediatric deaths in the U.S. as of August 14, 2025, reported to the Vaccine Adverse Event Reporting System (VAERS), but none were classified as "certain" in relation to vaccination. Seven deaths were "possibly" related, and two were "probably" linked, mostly involving myocarditis, a known risk. This contradicts a leaked internal memo claiming "at least 10 children have died after and because of receiving COVID-19 vaccination." Senator Ron Johnson has called for greater transparency regarding these findings.

• The FDA's analysis of Vaccine Adverse Event Reporting System (VAERS) data, covering 96 unique pediatric deaths reported by August 14, 2025, concluded that "no cases were classified as certain in relation to COVID-19 vaccination." This directly refutes prior claims of definitive vaccine-related child fatalities, emphasizing the lack of direct causal evidence in the agency's review.
• The report identified seven deaths as "possibly" related and two as "probably" linked to COVID-19 vaccines. The "probable" cases, while unlikely to be attributed to alternative etiologies, still do not rule out other causes. Most of these cases involved myocarditis, a known vaccine risk, but the report noted that fatal outcomes from myocarditis are not currently described in product labels, suggesting a gap in current labeling.
• Senator Ron Johnson (R-WI) publicly released these findings as part of a letter to Health Secretary Robert F. Kennedy, Jr., demanding greater transparency regarding vaccine safety. Johnson criticized the FDA's handling of VAERS data, suggesting that the sheer volume of reports should have raised alarms and that an "old algorithm" might have obscured safety signals, calling for a meeting to expedite discovery of alleged oversights.
• The press release notes a trend of dwindling sales for vaccine manufacturers, partly attributed to the rhetoric and policies of Robert F. Kennedy, Jr. Sanofi reported a 17% hit to vaccine sales, while Pfizer saw a 6% year-on-year decline in overall revenue for 2025, with its COVID-19 vaccine Comirnaty crashing 20% year-on-year to under $4.4 billion worldwide.

FDA's Latest Findings on Pediatric COVID-19 Vaccine Safety

Published safety and tolerability data from recent surveillance studies and clinical trials demonstrate that COVID-19 vaccines across all platforms exhibit predominantly mild to moderate adverse events that resolve within 3-4 days. The most frequently reported local reactions include injection site pain (observed in up to 71.7% of recipients), swelling, and erythema, while systemic reactions commonly encompass fever, fatigue, myalgia, and headache. Large-scale Australian surveillance data covering over 4.8 million individuals revealed adverse event following immunization (AEFI) rates ranging from 22.0% to 54.7% depending on vaccine type and dose number, with Comirnaty second dose showing the highest reporting rate. Laboratory derangements including decreased hemoglobin and elevated liver enzymes have been documented but remain clinically insignificant and self-limiting.

Platform-specific safety profiles reveal distinct patterns, with mRNA vaccines demonstrating higher association with serious vascular disorders compared to viral vector and inactivated vaccines, though direct causality remains unestablished. Viral vector and inactivated vaccines show increased incidence of serious gastrointestinal complications and infections, while inactivated vaccines specifically correlate with more frequent metabolic, musculoskeletal, immune system, and renal disorders. Demographic factors significantly influence adverse event reporting, with women showing 1.53-1.84 times higher odds of reporting AEFIs compared to men, and individuals with obesity, immunodeficiency, or chronic inflammatory conditions demonstrating elevated reporting rates.

Rare but serious adverse events of special interest include venous and arterial thrombotic events, myocarditis/pericarditis, and Bell's palsy, with incidence rates comparable across different populations studied. Severe delayed hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis occur rarely but have been documented, particularly in pediatric populations within 30 days post-vaccination. Neurological complications including Guillain-Barré syndrome, transverse myelitis, and acute disseminated encephalomyelitis represent extremely rare occurrences. Systematic reviews consistently indicate that COVID-19 vaccines maintain acceptable safety profiles with no definitive evidence of vaccine-induced serious adverse events, though continued post-marketing surveillance remains warranted for vulnerable populations including elderly, immunocompromised, pregnant women, and children.

Understanding Known Safety Signals and Public Concerns

Clinical trials for COVID-19 therapeutics have generated substantial safety data across multiple drug classes and patient populations. Recent studies demonstrate generally manageable safety profiles for most approved treatments, though some notable differences exist between therapeutic approaches.

• Monoclonal antibodies show favorable safety profiles, with adintrevimab demonstrating no drug-related serious adverse events and sotrovimab associated with lower adverse event rates compared to no treatment (OR 0.15, 95% CI: 0.02-0.86) in solid organ transplant recipients

• Antiviral agents exhibit comparable safety between treatments, with remdesivir versus sotrovimab showing equivalent adverse event rates (OR = 0.98, 95% CI: 0.39-2.47, p = 0.97), while favipiravir meta-analysis revealed no significant differences in adverse events compared to controls across 1,448 patients

• mRNA COVID-19 vaccines present distinct safety signals compared to influenza vaccines, including higher rates of systemic reactions (chills, myalgia, fatigue) and increased risk of manageable cardiovascular complications such as hypertensive crisis (adjusted ROR 12.72) and supraventricular tachycardia (adjusted ROR 7.94)

• IL-6 blocking agents demonstrate mixed safety profiles, with tocilizumab showing little difference in adverse event risk (RR 1.03, 95% CI: 0.95-1.12) while sarilumab evidence remains uncertain for both adverse events and serious adverse events

• Gastrointestinal adverse events emerge as the most frequent safety signal across multiple drug classes, including nausea, abdominal cramps, diarrhea, and vomiting, followed by cardiovascular, cutaneous, and hepatic manifestations

• Long-term safety data from deucravacitinib in psoriasis patients shows decreasing adverse event rates over time, with exposure-adjusted incidence rates declining from 229.23 to 131.68 per 100 person-years between 1-year and 4-year follow-up periods

Challenges Impacting COVID-19 Vaccine Uptake and Market

Current COVID-19 treatment approaches face significant obstacles that impact therapeutic effectiveness and global accessibility. While numerous repurposed drugs and novel therapies have been investigated, systematic limitations in research quality and coordination continue to hinder optimal patient outcomes. These challenges have created gaps between treatment availability and equitable access worldwide.

• Limited high-quality clinical evidence: Studies demonstrate few published investigations of high quality, with a low proportion of trials completed and the vast majority yielding negative results, undermining confidence in treatment protocols

• Insufficient investment in therapeutics development: Limited financial resources allocated to COVID-19 therapeutics development compared with vaccines has constrained the pipeline of effective treatment options

• Poor coordination of accessible therapies: Inadequate coordination of trials investigating accessible agents and their combinations, particularly in low- and middle-income countries (LMICs), has resulted in fragmented treatment approaches

• Suboptimal early pandemic trial design: Studies initiated during the first wave (March-June 2020) were predominantly non-international, non-commercial, and non-placebo-controlled, limiting the robustness of evidence generation

• Narrow focus on drug repositioning: Clinical trials concentrated heavily on therapeutic repositioning (72.1% of studies in Spain), potentially limiting exploration of novel therapeutic mechanisms

• Ongoing vaccine development challenges: Despite extensive research efforts by various nations and companies, developing efficient and economical vaccines that ensure equitable global access remains a persistent obstacle to pandemic control

Pediatric COVID-19 Vaccine Safety: Clarity Amidst Ongoing Scrutiny

The recent analysis from the FDA, concluding no definitive link between COVID-19 vaccines and pediatric deaths, marks a pivotal moment in the ongoing public health dialogue. While the report acknowledges a small number of "possibly" or "probably" related deaths, predominantly associated with myocarditis, it largely reinforces the extensive body of evidence supporting the overall safety profile of these vaccines in children.

This clarity is particularly significant given the persistent challenges of vaccine hesitancy and the spread of misinformation. Studies have consistently shown that COVID-19 vaccines are safe and effective in pediatric populations, significantly reducing the risk of severe disease, hospitalization, and serious complications like multisystem inflammatory syndrome in children (MIS-C). While rare adverse events such as myocarditis and pericarditis have been identified, especially in adolescent males after the second dose, these are generally mild and transient, and the benefits of vaccination continue to outweigh these risks. For instance, active surveillance data indicate that the incidence of myocarditis in children aged 5-11 years is very rare, though higher rates are observed in male adolescents and young adults.

From a strategic perspective, this report provides a robust, evidence-based foundation for public health campaigns to rebuild and maintain vaccine confidence among parents. Transparent communication from regulatory bodies is crucial in countering narratives that misrepresent data from surveillance systems like VAERS. However, the acknowledgment of rare adverse events also underscores the ongoing need for meticulous pharmacovigilance. This includes refining vaccination strategies, such as optimizing dosing intervals or considering specific vaccine types for young males, to further mitigate these known, albeit rare, risks. The continued monitoring of these events remains paramount to ensure long-term safety and public trust.

Ultimately, this latest analysis serves as a critical data point, reinforcing the overall safety profile of pediatric COVID-19 vaccines. It underscores the ongoing commitment to vaccine safety surveillance and the imperative for clear, evidence-based communication to empower parents and healthcare providers, ensuring that public health decisions are grounded in scientific rigor.